Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad Tang

Showing results (1-10 of 220) with videos related to

Pageof 22
Sort By:
Seminars in Immunopathology|April 12, 2011
Potential barriers to therapeutics utilizing pluripotent cell derivatives: intrinsic immunogenicity of in vitro maintained and matured populationsChad Tang, Micha Drukker
JAMA Oncology|March 7, 2024
Charting the Path to Systemic Therapy De-escalation-Oligometastatic Kidney Cancer as a ParadigmChad Tang, Pavlos Msaouel
Journal of Thoracic Disease|January 10, 2017
PD-L1 expression in lung cancerChad Tang, Joe Y Chang
Cancer|March 12, 2020
Reply to Multidisciplinary clinics: A possible means to help to eliminate racial disparities in prostate cancerChad Tang, Karen Hoffman, Deborah Kuban
Oncotarget|February 2, 2012
The safety of embryonic stem cell therapy relies on teratoma removalChad Tang, Irving L Weissman, Micha Drukker
Cancer Journal (Sudbury, Mass.)|November 26, 2024
Current State of Stereotactic Body Radiation Therapy for Genitourinary MalignanciesAlexander D Sherry, Neil Desai, Chad Tang
Journal of Immunotherapy and Precision Oncology|February 8, 2023
Oligometastases: We Have a Hammer, but What Exactly is the Nail?Ibrahim Abu-Gheida, Wen Jiang, Chad Tang
Oncotarget|July 28, 2021
Multidisciplinary clinics in prostate cancerBrian De, Deborah A Kuban, Chad Tang
Methods in Molecular Biology (Clifton, N.J.)|June 13, 2013
Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivativesChad Tang, Irving L Weissman, Micha Drukker
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2017
Phase I Trial: SABR and Ipilimumab-ResponseChad Tang, James W Welsh, David Hong
Pageof 22

Showing results (1-10 of 220) with videos related to

Sort By:
Pageof 22
Seminars in Immunopathology|April 12, 2011
Potential barriers to therapeutics utilizing pluripotent cell derivatives: intrinsic immunogenicity of in vitro maintained and matured populationsChad Tang, Micha Drukker
JAMA Oncology|March 7, 2024
Charting the Path to Systemic Therapy De-escalation-Oligometastatic Kidney Cancer as a ParadigmChad Tang, Pavlos Msaouel
Journal of Thoracic Disease|January 10, 2017
PD-L1 expression in lung cancerChad Tang, Joe Y Chang
Cancer|March 12, 2020
Reply to Multidisciplinary clinics: A possible means to help to eliminate racial disparities in prostate cancerChad Tang, Karen Hoffman, Deborah Kuban
Oncotarget|February 2, 2012
The safety of embryonic stem cell therapy relies on teratoma removalChad Tang, Irving L Weissman, Micha Drukker
Cancer Journal (Sudbury, Mass.)|November 26, 2024
Current State of Stereotactic Body Radiation Therapy for Genitourinary MalignanciesAlexander D Sherry, Neil Desai, Chad Tang
Journal of Immunotherapy and Precision Oncology|February 8, 2023
Oligometastases: We Have a Hammer, but What Exactly is the Nail?Ibrahim Abu-Gheida, Wen Jiang, Chad Tang
Oncotarget|July 28, 2021
Multidisciplinary clinics in prostate cancerBrian De, Deborah A Kuban, Chad Tang
Methods in Molecular Biology (Clifton, N.J.)|June 13, 2013
Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivativesChad Tang, Irving L Weissman, Micha Drukker
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2017
Phase I Trial: SABR and Ipilimumab-ResponseChad Tang, James W Welsh, David Hong
Pageof 22